APA (7th ed.) Citation

Michaeli, D., Michaeli, C. T., Albers, S., Boch, T., & Michaeli, J. (2024). Special FDA designations for drug development: Orphan, fast track, accelerated approval, priority review, and breakthrough therapy. The European journal of health economics, 25(6), . https://doi.org/10.1007/s10198-023-01639-x

Chicago Style (17th ed.) Citation

Michaeli, Daniel, Christoph T. Michaeli, Sebastian Albers, Tobias Boch, and Julia Michaeli. "Special FDA Designations for Drug Development: Orphan, Fast Track, Accelerated Approval, Priority Review, and Breakthrough Therapy." The European Journal of Health Economics 25, no. 6 (2024). https://doi.org/10.1007/s10198-023-01639-x.

MLA (9th ed.) Citation

Michaeli, Daniel, et al. "Special FDA Designations for Drug Development: Orphan, Fast Track, Accelerated Approval, Priority Review, and Breakthrough Therapy." The European Journal of Health Economics, vol. 25, no. 6, 2024, https://doi.org/10.1007/s10198-023-01639-x.